ArticleOphthalmology and therapy2023
LIGHTSITE II Randomized Multicenter Trial: Evaluation of Multiwavelength Photobiomodulation in Non-exudative Age-Related Macular Degeneration.
Article in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03878420 (A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE II)
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- HONU: A Multicenter, Prospective, Observational Study of the Progression of Intermediate Age-Related Macular Degeneration.Ophthalmology science · 2026Article
- Photobiomodulation for Photoreceptor Rescue in Retinal Disease: Mitochondrial, Redox, Vascular, and Translational Perspectives-A Narrative Review.Antioxidants (Basel, Switzerland) · 2026Review
- Near-Infrared and Red-Light Photobiomodulation for Ocular Aging and Diseases: A Narrative Review.Ophthalmology and therapy · 2026Review
- Non neovascular Age - related macular degeneration - Review on clinical and imaging advances.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Review
- Photobiomodulation in Age-Related Macular Degeneration: A Mitochondrial Bioenergetic Framework and Translational Perspective.Life (Basel, Switzerland) · 2026Review
- Molecular Mechanisms of Photobiomodulation in Retinal Diseases: Cytochrome c Oxidase, Mitochondrial Bioenergetics and Cytoprotective Signalling.International journal of molecular sciences · 2026Review
- Functional and Structural Outcomes of Photobiomodulation Therapy in Dry Age-Related Macular Degeneration: A Single-Center Experience.Journal of clinical medicine · 2026Article
- Short-Term Effects of Low-Level Red-Light Therapy on Central Retinal Function: A Combined Pattern ERG and Photopic ERG Study.Vision (Basel, Switzerland) · 2026Article
- Imaging Biomarkers To Predict Progression of Intermediate AMD with Avascular Pigment Epithelial Detachment in the University of Colorado AMD Registry.Research square · 2026Article
- Effect of Repeated Medium-Dose Red Laser Irradiation on Ocular Tissues in Guinea Pigs.Investigative ophthalmology & visual science · 2026Article
- Letter to the Editor Regarding "Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration".Ophthalmology and therapy · 2026Article
- From light to healing: photobiomodulation therapy in medical disciplines.Journal of translational medicine · 2025Review
- Mechanisms and Functions of Chromophore Regeneration in the Classical Visual Cycle: Implications for Retinal Disease Pathogenesis and Therapy.Biomolecules · 2025Review
- Multiwavelength Photobiomodulation Improves Multiple Aspects of Visual Function in Early-Stage Dry Age-Related Macular Degeneration.Ophthalmology and therapy · 2025Article
- Light buckets and laser beams: mechanisms and applications of photobiomodulation (PBM) therapy.GeroScience · 2025Review
- Is Multiwavelength Photobiomodulation Effective and Safe for Age-Related Macular Degeneration? A Systematic Review and Meta-Analysis.Ophthalmology and therapy · 2025Article
- Effect of Photobiomodulation on Proliferative Changes in the Retina: Evidence from an In Vitro Model of PVR.Advances in experimental medicine and biology · 2025Article
- Effects of Photobiomodulation on Nervous System Disorders: A Narrative Review.Journal of lasers in medical sciences · 2025Review
- Short-term efficacy of photobiomodulation in early and intermediate age-related macular degeneration: the PBM4AMD study.Eye (London, England) · 2024Article
- Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration.Ophthalmology and therapy · 2024Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 9 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPhotobiomodulation (PBM) represents a potential treatment for non-exudative age-related macular degeneration (AMD). PBM uses wavelengths of light to target components of the mitochondrial respiratory chain to improve cellular bioenergetic outputs. The aim of this study was to further investigate the effects of PBM on clinical, quality of life (QoL) and anatomical outcomes in subjects with intermediate stage non-exudative AMD.
methodsThe multicenter LIGHTSITE II study was a randomized clinical trial evaluating safety and efficacy of PBM in intermediate non-exudative AMD. The LumiThera Valeda® Light Delivery System delivered multiwavelength PBM (590, 660 and 850 nm) or sham treatment 3 × per week over 3-4 weeks (9 treatments per series) with repeated treatments at baseline (BL), 4 and 8 months. Subjects were enrolled with 20/32 to 20/100 best-corrected visual acuity (BCVA) and no central geographic atrophy (GA) within the central fovea (500 μm).
resultsLIGHTSITE II enrolled 44 non-exudative AMD subjects (53 eyes). PBM-treated eyes showed statistically significant improvement in BCVA at 9 months (n = 32 eyes, p = 0.02) with a 4-letter gain in the PBM-treated group versus a 0.5-letter gain in the sham-treated group (ns, p < 0.1) for patients that received all 27 PBM treatments (n = 29 eyes). Approximately 35.3% of PBM-treated eyes showed ≥ 5-letter improvement at 9 months. Macular drusen volume was not increased over time in the PBM-treated group but did show increases in the sham-treated group. While PBM and sham groups both showed GA lesion growth in the trial period, there was 20% less growth in the PBM group over 10 months, suggesting potential disease-modifying effects. No safety concerns or signs of phototoxicity were observed.
conclusionThese results confirm previous clinical testing of multiwavelength PBM and support treatment with Valeda as a novel therapy with a unique mechanism of action as a potential treatment for non-exudative AMD.
trial registrationClinicaltrial.Gov Registration Identifier: NCT03878420.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.